CLDX Hedge Fund Ownership (Q1 2026)

Celldex Therapeutics Inc New (CLDX)

219 + Investors. Track Smart Money conviction in CLDX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CLDX

Based on 222 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q

For 4 consecutive quarters, more hedge funds added CLDX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

222 hedge funds hold CLDX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +31% more funds vs a year ago

fund count last 6Q

+52 new funds entered over the past year (+31% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 62% buying

125 buying76 selling

Last quarter: 125 funds were net buyers (57 opened a brand new position + 68 added to an existing one). Only 76 were sellers (58 trimmed + 18 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+30 vs last Q)

new funds entering per quarter

Funds opening a new CLDX position: 37 → 30 → 27 → 57. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔒

51% of holders stayed for 2+ years

■ 51% conviction (2yr+) ■ 25% medium ■ 24% new

114 out of 222 hedge funds have held CLDX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💰

Price up while funds trimmed (+15% value, -1% shares)

Value

+15%

Last quarter: total value of institutional CLDX holdings rose +15% even though funds reduced share count by 1%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.

📈

Growing discovery — still being found

27 → 37 → 30 → 27 → 57 new funds/Q

New funds entering each quarter: 37 → 30 → 27 → 57. A growing number of institutions are discovering CLDX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 57% veterans vs 28% newcomers

■ 57% veterans ■ 14% 1-2yr ■ 28% new

Entry-cohort mix of 229 holders: 131 (57%) are 2+ year veterans, 33 entered 1–2 years ago, and 65 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 45% AUM from top-100 funds

45% from top-100 AUM funds

46 of 222 holders are among the 100 largest funds by AUM, controlling 45% of total institutional value in CLDX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.9

out of 10

Low Exit Risk

Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	219	183	19.67%
13F Shares	73M	73M	-0.76%
Total Value	$2.23B	$1.94B	15.29%
New Positions	54	27	+27
Increased Positions	68	59	+9
Closed Positions	18	23	-5
Reduced Positions	56	60	-4
Total Calls	3	2	50.0%
Total Puts	4	2	100.0%
PUT/CALL Ratio	1.33	1.0	Bearish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

219

183

19.67%

13F Shares

73M

-0.76%

Total Value

$2.23B

$1.94B

15.29%

New Positions

+27

Increased Positions

Closed Positions

-5

Reduced Positions

-4

Total Calls

50.0%

Total Puts

100.0%

PUT/CALL Ratio

1.33

1.0

Bearish

Institutional Holders (2026 Q2)

219 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CLDX. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CLDX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Kynam Capital Management, LP	10.95%	5,322,908	$198.1M
2	Elmind Capital, LP	9.25%	990,000	$36.8M
3	Superstring Capital Management LP	6.76%	287,583	$10.7M
4	5AM Venture Management, LLC	6.43%	497,270	$18.5M
5	Foresite Capital Management VI LLC	5.09%	879,713	$32.7M
6	GordonMD Global Investments LP	5.04%	279,720	$10.4M
7	Eversept Partners, LP	3.45%	1,785,941	$66.5M
8	Logos Global Management LP	3.36%	2,100,000	$78.1M
9	TSP Capital Management Group, LLC	3.30%	371,127	$13.8M
10	Commodore Capital LP	2.99%	1,350,000	$50.2M
11	Rosalind Advisors, Inc.	2.76%	200,000	$7.4M
12	Novo Holdings A/S	2.21%	1,025,000	$38.1M
13	Palo Alto Investors LP	2.06%	399,856	$14.9M
14	Propel Bio Management, LLC	2.02%	103,695	$3.9M
15	Ikarian Capital, LLC	1.92%	478,500	$17.8M
16	Tetragon Partners GP Ltd	1.70%	290,441	$10.8M
17	Deep Track Capital, LP	1.59%	2,939,151	$109.4M
18	Rock Springs Capital Management LP	1.27%	699,146	$26.0M
19	Birchview Capital, LP	1.22%	69,900	$2.6M
20	Affinity Asset Advisors, LLC	1.18%	700,000	$26.0M
21	Sphera Funds Management LTD.	1.17%	240,868	$9.0M
22	Stempoint Capital LP	1.14%	178,412	$6.6M
23	PFM Health Sciences, LP	1.09%	342,751	$12.8M
24	Redmile Group, LLC	1.08%	433,921	$16.1M
25	ADAR1 Capital Management, LLC	1.05%	619,542	$23.1M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Celldex Therapeutics Inc New (CLDX)

What does the Smart Money Trend signal show for CLDX?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added CLDX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CLDX?

More buyers than sellers — 62% buying: Last quarter: 125 funds were net buyers (57 opened a brand new position + 68 added to an existing one). Only 76 were sellers (58 trimmed + 18 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CLDX holders?

Elite ownership — 45% AUM from top-100 funds: 46 of 222 holders are among the 100 largest funds by AUM, controlling 45% of total institutional value in CLDX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CLDX?

51% of holders stayed for 2+ years: 114 out of 222 hedge funds have held CLDX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Celldex Therapeutics Inc New (CLDX)

Smart Money Signals — CLDX

Buying streak — 4 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +31% more funds vs a year ago

More buyers than sellers — 62% buying

More new buyers each quarter (+30 vs last Q)

51% of holders stayed for 2+ years

Price up while funds trimmed (+15% value, -1% shares)

Growing discovery — still being found

Veteran-anchored — 57% veterans vs 28% newcomers

Elite ownership — 45% AUM from top-100 funds

Institutional Sentiment Summary — CLDX

Hedge Fund Ownership: CLDX

Market Analysis: CLDX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CLDX

Hedge Fund Positioning: CLDX

Statistics: CLDX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Celldex Therapeutics Inc New (CLDX)

Welcome to 13Foresight!